Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN51 in early Alzheimer's disease
NCT06677203Phase 2Terminated
- Sponsor
- Asceneuron SA
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ASN51 in Alzheimer's disease (AD), sponsored by Asceneuron SA. Started Oct 2024; status: terminated.
02
Drugs
ASN51
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06677203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06677203.